NDAORALTABLET
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
EQUAGESIC (aspirin; meprobamate) by PharmaIN is clinical pharmacology meprobamate is a carbamate derivative which has been shown (in animal and/or human studies) to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Approved for anxiety. First approved in 1960.
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Equagesic is a fixed-dose oral tablet combining aspirin (nonnarcotic analgesic with antipyretic and anti-inflammatory properties) and meprobamate (a carbamate derivative acting on the thalamus and limbic system). It is indicated for anxiety and pain management. The product represents a legacy anxiolytic-analgesic combination approved in 1960.
LOE Approaching
Product is in decline phase with minimal competitive advantage; team size likely reduced and focused on lifecycle management rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown (in animal and/or human studies) to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Aspirin is a nonnarcotic analgesic with antipyretic and anti-inflammatory…
Indications (1)
Career Relevance
Working on Equagesic offers minimal career growth potential; the product is in managed decline with zero linked job openings and no pipeline expansion. Professionals assigned to this brand typically handle maintenance-only responsibilities and may face team reductions as Part D spending and market share erode further.
Worked on EQUAGESIC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.